Kakyung Kim

Archives
Log in
Subscribe
October 27, 2026

๐Ÿ“ˆ econ-radar 2026-10-27 ยท ESMO 2026 ADC ๊ฒฐ์‚ฐ: ๋ฐ”์ด์˜ค๋งˆ์ปค๊ฐ€ ์Šน๋ถ€๋ฅผ ๊ฐ€๋ฅธ๋‹ค

๐Ÿ“ˆ econ-radar 2026-10-27 ยท ESMO 2026 ADC ๊ฒฐ์‚ฐ: ๋ฐ”์ด์˜ค๋งˆ์ปค๊ฐ€ ์Šน๋ถ€๋ฅผ ๊ฐ€๋ฅธ๋‹ค

๐Ÿ“ˆ econ-radar ๋ฐ์ผ๋ฆฌ

2026-10-27

์ œ์•ฝยท๋ฐ”์ด์˜คยทAI์— ๋ฌด๊ฒŒ๋ฅผ ๋‘” ๊ฒฝ์ œ ๋ฐ์ผ๋ฆฌ โ€” ์‚ฐ์—…๊ตฌ์กฐยทํˆฌ์žยท์‹œ์žฅ 3๋ Œ์ฆˆ

At a Glance

๐Ÿ’ฐ ๋‚ด์ผ(10/28) FOMC ๋™๊ฒฐ(87% ํ™•๋ฅ )๊ณผ AlphabetยทMicrosoft ์–ด๋‹์Šค๊ฐ€ ๊ฒน์ณ, AI ์„ค๋น„ํˆฌ์ž๊ฐ€ ์‹ค๋งค์ถœ๋กœ ์ „ํ™˜๋˜๊ณ  ์žˆ๋Š”์ง€ ๊ณต์‹ ์ˆ˜์น˜๋กœ ์ฒ˜์Œ ํ™•์ธํ•˜๋Š” ๋‚ ์ด๋‹ค.

๐Ÿงฌ ESMO 2026 ํ๋ง‰์ผ, Pfizer IB6 ADC๋Š” nsq-NSCLC ์ „์ฒด ์ง‘๋‹จ OS์—์„œ ๊ณ ๋ฐฐ๋ฅผ ๋งˆ์…จ๊ณ  AZ๋Š” ๋ฐฉ๊ด‘์•”ยท์œ„์•” ๋‘ ์ ์‘์ฆ์—์„œ Phase 3 ์–‘์„ฑ์„ ๋™์‹œ์— ์™„์„ฑํ–ˆ๋‹ค. ๊ฐ™์€ ADC๋ผ๋„ ํƒ€๊นƒ ์„ ํƒ๊ณผ ํ™˜์ž ์„ ๋ณ„ ์ „๋žต์— ๋”ฐ๋ผ ๊ฒฐ๊ณผ๊ฐ€ ์ •๋ฐ˜๋Œ€๋กœ ๊ฐˆ๋ ธ๋‹ค.

๐Ÿ”ฉ SKํ•˜์ด๋‹‰์Šคยท์‚ผ์„ฑ์ „์ž Q3 ์‹ค์ ์ด 10/29 ๋‚˜๋ž€ํžˆ ๋‚˜์˜จ๋‹ค. HBM4(๊ณ ๋Œ€์—ญํญ๋ฉ”๋ชจ๋ฆฌ 4์„ธ๋Œ€) ๋งค์ถœ์ด ์ฒ˜์Œ ๋ฐ˜์˜๋˜๋Š” ๋ถ„๊ธฐ๋กœ, AI ๋ฉ”๋ชจ๋ฆฌ ์ ์œ ์œจ ์‹ธ์›€์˜ ์ฒซ ์ˆ˜์น˜ ์„ฑ์ ํ‘œ๊ฐ€ ๊ณต๊ฐœ๋œ๋‹ค.

Today's Top 5

AIMacro

1. FOMC D-1 + AlphabetยทMicrosoft ์–ด๋‹์Šค D-1 โ€” AI capex ROI ์ฒซ ๋ฒˆ์งธ ๊ณต์‹ ์ฑ„์ 

10์›” 28์ผ(ํ™”) FOMC ๊ธˆ๋ฆฌ ๊ฒฐ์ •(ํ˜„์ง€์‹œ๊ฐ„ 14:00ยทํ•œ๊ตญ ์‹œ๊ฐ„ 10/29 03:00), Alphabet Q3, Microsoft FY2027 Q1์ด ํ•œ ๋‚ ์— ๋ฐœํ‘œ๋œ๋‹ค. ์„ ๋ฌผ์‹œ์žฅ์€ ํ˜„ํ–‰ 3.75~4.00% ๋™๊ฒฐ ํ™•๋ฅ ์„ 87%(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”)๋กœ ๋ฐ˜์˜ํ•˜๊ณ  ์žˆ๋‹ค. Warsh ์˜์žฅ์€ "์˜ฌํ•ด ๋‚จ์€ ํšŒ์˜์—์„œ ๋ฌด์—‡์„ ํ• ์ง€ ์ง€๊ธˆ ๋งํ•˜์ง€ ์•Š๊ฒ ๋‹ค"๊ณ  ๋ฐํ˜”๋‹ค. Microsoft Azure ๊ฐ€์ด๋˜์Šค๋Š” 44~45% CC(๋ถˆ๋ณ€ํ†ตํ™”, Constant Currency) ์„ฑ์žฅ์ด๋ฉฐ AI ๋น„์ฆˆ๋‹ˆ์Šค ์—ฐ๊ฐ„ ๋Ÿฐ๋ ˆ์ดํŠธ(run-rate)๋Š” 370์–ต๋‹ฌ๋Ÿฌ(์•ฝ 51์กฐ3,000์–ต์›ยทYoY +123%)๋‹ค. Alphabet Google Cloud๋Š” Q2 ๊ธฐ์ค€ YoY +82%ยท๋งˆ์ง„ 31.2%๋ฅผ ๊ธฐ๋กํ–ˆ๋‹ค. Meta๊ฐ€ 2026 ์„ค๋น„ํˆฌ์ž(capex) 1,350~1,450์–ต๋‹ฌ๋Ÿฌ(์•ฝ 187์กฐ4,000์–ต~201์กฐ2,000์–ต์›)๋ฅผ ๊ณต์–ธํ•˜๋ฉฐ AI ROI ๋…ผ์Ÿ์„ ๊ณต๋ก ํ™”ํ•œ ์ดํ›„, ๋‘ ํšŒ์‚ฌ์˜ ์‹ค์ ์ด AI ํˆฌ์ž ROI ํŒ๋‹จ์˜ ๊ธฐ์ค€์„ ์ด ๋œ๋‹ค.

โ†— Barchart FOMC ํ™•๋ฅ  ๋ถ„์„

Market

2. Pfizer SigVie-002 Phase 3 โ€” nsq-NSCLC ์ „์ฒด ์ง‘๋‹จ OS ๋ฏธ๋‹ฌ

Pfizer์˜ IB6(CEACAM5 ํ‘œ์ ) ํ•ญ์ฒด์•ฝ๋ฌผ๊ฒฐํ•ฉ์ฒด(ADC) ์‹œ๊ทธ๋ณดํƒ€ํˆฌ๊ทธ ๋ฒ ๋„ํ‹ด(sigvotatug vedotin)์ด 10์›” 25์ผ ESMO LBA68์—์„œ ์ด์ „ ์น˜๋ฃŒ๋ฐ›์€ ๋น„ํŽธํ‰ ๋น„์†Œ์„ธํฌํ์•”(nsq-NSCLC) ์ „์ฒด ์ง‘๋‹จ ์ „์ฒด์ƒ์กด(OS) 1์ฐจ ํ‰๊ฐ€๋ณ€์ˆ˜๋ฅผ ๋‹ฌ์„ฑํ•˜์ง€ ๋ชปํ–ˆ๋‹ค๊ณ  ๋ฐœํ‘œ๋๋‹ค. 2์ฐจ ์น˜๋ฃŒ(2L) ์„œ๋ธŒ๊ทธ๋ฃน(์ „์ฒด์˜ ์•ฝ 2/3)์—์„œ OSยทPFS "๊ฐ•ํ•œ ๊ฒฝํ–ฅ(trend)"์ด ๊ด€์ฐฐ๋์œผ๋‚˜ ์ˆ˜์น˜๋Š” ๊ณต๊ฐœ๋˜์ง€ ์•Š์•˜๋‹ค. ํƒ์ƒ‰์  ๋ถ„์„์—์„œ IB6 ๋ฐœํ˜„๊ณผ ๋ฐ˜์‘ ์‚ฌ์ด์— ๋šœ๋ ทํ•œ ๊ด€๊ณ„๊ฐ€ ์—†๋‹ค๊ณ  ํ™•์ธ๋๋‹ค. Pfizer๋Š” "1์ฐจ ์น˜๋ฃŒ pembrolizumab ๋ณ‘์šฉ ๊ฐœ๋ฐœ์„ ๊ณ„์†ํ•œ๋‹ค"๊ณ  ๋ฐํ˜”๋‹ค.

โ†— AJMC SigVie-002 ๊ฒฐ๊ณผ

Market

3. AZ VOLGA Phase 3 โ€” ๊ทผ์นจ์œค์„ฑ๋ฐฉ๊ด‘์•” EFS 49%ยทOS 42% ์œ„ํ—˜ ๊ฐ์†Œ

AstraZeneca์˜ VOLGA Phase 3๊ฐ€ 10์›” 23์ผ ESMO Presidential Symposium LBA2์—์„œ ์ „์ฒด ๋ฐ์ดํ„ฐ๋ฅผ ๋ฐœํ‘œํ–ˆ๋‹ค. ์‹œ์Šคํ”Œ๋ผํ‹ด ๋ถ€์ ํ•ฉยท๊ฑฐ๋ถ€ ๊ทผ์นจ์œค์„ฑ๋ฐฉ๊ด‘์•”(MIBC, muscle-invasive bladder cancer) ํ™˜์ž์—์„œ ๋”๋ฐœ๋ฃจ๋ง™(Imfinzi)+์—”ํฌํˆฌ๋ง™ ๋ฒ ๋„ํ‹ด(EV, Nectin-4 ADC)+์ˆ˜์ˆ  ๋ณ‘ํ•ฉ์ด ์ˆ˜์ˆ  ๋‹จ๋… ๋Œ€๋น„ ์‚ฌ๊ฑด๋ฐœ์ƒ๋ฌด์งˆํ™˜์ƒ์กด(EFS) ์œ„ํ—˜ 49% ๊ฐ์†Œ(HR 0.51, 95% CI 0.38โ€“0.67, p<0.0001)ยท์ „์ฒด์ƒ์กด(OS) ์œ„ํ—˜ 42% ๊ฐ์†Œ(HR 0.58, 95% CI 0.40โ€“0.83, p=0.0027)๋ฅผ ๋‹ฌ์„ฑํ–ˆ๋‹ค. Tremelimumab ๋ณ‘์šฉ๊ตฐ์€ EFS ๊ฐœ์„ ๋์œผ๋‚˜ OS ํ†ต๊ณ„์  ์œ ์˜์„ฑ ๋ฏธ์ถฉ์กฑ. ๋”๋ฐœ๋ฃจ๋ง™์˜ ๋ฐฉ๊ด‘์•” ์„ธ ๋ฒˆ์งธ Phase 3 ์–‘์„ฑ์ด๋‹ค(NIAGARAยทPOTOMAC ์ดํ›„).

โ†— AstraZeneca ๋ณด๋„์ž๋ฃŒ(5/14)

Semiconductor

4. SKํ•˜์ด๋‹‰์Šคยท์‚ผ์„ฑ์ „์ž Q3 D-2 โ€” HBM4 ์ฒซ ๋งค์ถœ ๋ฐ˜์˜ ๋ถ„๊ธฐ

SKํ•˜์ด๋‹‰์Šค(000660.KS) Q3 2026 ์‹ค์ ์ด 10์›” 29์ผ(์ˆ˜) ๋ฐœํ‘œ๋œ๋‹ค. FnGuide ์ปจ์„ผ์„œ์Šค ์˜์—…์ด์ต 76์กฐ9,600์–ต์›(OPM ์•ฝ 78.4%)์ด๋ฉฐ, D๋žจ(DRAM) ํŒ๊ฐ€ QoQ +22%ยท๋‚ธ๋“œ(NAND) +15% QoQ๊ฐ€ ๋ฉ”๋ฆฌ์ธ ์ฆ๊ถŒ ์ถ”์ •์น˜๋‹ค. Q3๋ถ€ํ„ฐ ์—”๋น„๋””์•„ ๋ฒ ๋ผ ๋ฃจ๋นˆ(Vera Rubin, GB300) ํ”Œ๋žซํผ ํ–ฅ HBM4(๊ณ ๋Œ€์—ญํญ๋ฉ”๋ชจ๋ฆฌ 4์„ธ๋Œ€) ๋งค์ถœ์ด ์ฒ˜์Œ ๋ฐ˜์˜๋œ๋‹ค. ์‚ผ์„ฑ์ „์ž๋Š” 10์›” 8์ผ Q3 ์ž ์ •์‹ค์ (์˜์—…์ด์ต 107์กฐ4,000์–ต์›, YoY +783%)์„ ๋ฐœํ‘œํ–ˆ์œผ๋ฉฐ 10/29 ์‚ฌ์—…๋ถ€๋ณ„ ์ƒ์„ธ๊ฐ€ ๋‚˜์˜จ๋‹ค. JP๋ชจ๊ฑด ์ถ”์ • ๊ธฐ์ค€ Q2 HBM ์‹œ์žฅ์ ์œ ์œจ์€ SKํ•˜์ด๋‹‰์Šค 50%ยท์‚ผ์„ฑ์ „์ž 33%ยทMicron 18%์ด๋ฉฐ, Q1 ๋Œ€๋น„ ๊ฒฉ์ฐจ๊ฐ€ 37%ํฌ์ธํŠธ์—์„œ 17%ํฌ์ธํŠธ๋กœ ์ขํ˜€์กŒ๋‹ค.

โ†— ๋จธ๋‹ˆํˆฌ๋ฐ์ด(10/19)

Market

5. MerckยทKelun-Biotech sac-TMT โ€” ํ•œ ํ•™ํšŒ์—์„œ Phase 3 ์„ธ ํŽธ ๋™์‹œ ๋ฐœํ‘œ

Merck์™€ Kelun-Biotech(SKB264/MK-2870)์˜ Trop-2 ํ‘œ์  ADC ์‚ฌํฌ-TMT(sacituzumab tirumotecan, ์‚ฌํฌ์ดํˆฌ์ฃผ๋ง™ ํ‹ฐ๋ฃจ๋ชจํ…Œ์นธ)๊ฐ€ ESMO 2026 ๋‹จ์ผ ํ•™ํšŒ์—์„œ ์„ธ ๊ฑด์˜ Phase 3 ๋ฐ์ดํ„ฐ๋ฅผ ๋ƒˆ๋‹ค. TroFuse-005(LBA11, ์ž๊ถ๋‚ด๋ง‰์•” 2์ฐจ ์ด์ƒ, N=776)๋Š” 10์›” 26์ผ ๋ฐœํ‘œ๋์œผ๋ฉฐ ํƒ‘๋ผ์ธ(5์›” 18์ผ ํ™•์ธ) ๊ธฐ์ค€ OSยทPFS ์ด์ค‘ 1์ฐจ ๋‹ฌ์„ฑ์ด ํ™•์ธ๋๋‹ค. OptiTROOP-Lung04(LBA67)๋Š” EGFR ๋Œ์—ฐ๋ณ€์ด nsq-NSCLC TKI ์‹คํŒจ ํ›„ ์ตœ์ข… OS ๋ถ„์„์œผ๋กœ, ESMO 2025 ์ค‘๊ฐ„ ๋ฐ์ดํ„ฐ(OS HR 0.60, p=0.0006) ์ดํ›„ ์ตœ์ข… ์ˆ˜์น˜๋Š” ํ™•์ธ ๋Œ€๊ธฐ ์ƒํƒœ๋‹ค. OptiTROOP-Lung06(LBA66)์€ PD-L1 ์Œ์„ฑ nsq-NSCLC 1์ฐจ ์น˜๋ฃŒ sac-TMT+pembrolizumab vs ํ™”ํ•™์š”๋ฒ•+pembrolizumab ๊ฒฐ๊ณผ๋กœ ์ˆ˜์น˜ ํ™•์ธ ๋Œ€๊ธฐ.

โ†— Merck TroFuse-005 ํƒ‘๋ผ์ธ(5/18)

๐Ÿ—ฃ ์˜ค๋Š˜์˜ ํ™”์ œ

ESMO 2026์—์„œ ADC ์„ฑํŒจ๋ฅผ ๊ฐ€๋ฅธ ๊ฒƒ์€ ํƒ€๊นƒ ๋‹จ๋ฐฑ์งˆ ๋ฐœํ˜„ ๋ณดํŽธ์„ฑ๊ณผ ํ™˜์ž ์„ ๋ณ„ ์ „๋žต์ด์—ˆ๋‹ค. ๋ฐ”์ด์˜ค๋งˆ์ปค ์—†์ด ์ „์ฒด ์ง‘๋‹จ OS๋ฅผ ๋…ธ๋ฆฐ ์‹œํ—˜์€ ์‹คํŒจํ–ˆ๊ณ , ๋ช…ํ™•ํ•œ ์„ ๋ณ„ ๊ธฐ์ค€์„ ๊ฐ€์ง„ ์‹œํ—˜์€ ์–‘์„ฑ์„ ๋ƒˆ๋‹ค.

์ „์ฒด ๋ฆฌํฌํŠธ ๋ณด๊ธฐ โ†’

Deep Dive ยท Demand ยท Investment ยท Companies ยท Sources ์ „์ฒด๋Š” ์œ„ ๋งํฌ์—์„œ ๋ณด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ…”๋ ˆ๊ทธ๋žจ @econradar ๋กœ๋„ ๋ฐ›๊ธฐ

econ-radar ยท 2026-10-27

ํˆฌ์ž ์ฐธ๊ณ ์šฉ ์ •๋ณด์ž…๋‹ˆ๋‹ค. ์ตœ์ข… ํŒ๋‹จ๊ณผ ์ฑ…์ž„์€ ๋ณธ์ธ์—๊ฒŒ ์žˆ์Šต๋‹ˆ๋‹ค.

Don't miss what's next. Subscribe to Kakyung Kim:
โ† Newer ๐Ÿ“ˆ econ-radar 2026-10-28 ยท AI ์„ค๋น„ํˆฌ์ž(capital expenditure)์™€ ROI Older โ†’ ๐Ÿ“ˆ econ-radar 2026-10-26 ยท EGFR ๋Œ์—ฐ๋ณ€์ด ํ์•”์˜ ์น˜๋ฃŒ ์ง€ํ˜•์ด ๋‹ค์‹œ ๋ฐ”๋€๋‹ค
Powered by Buttondown, the easiest way to start and grow your newsletter.